Applications of D-(+)-(2-Chlorophenyl)Glycine in Industrial Manufacturing

D-(+)-(2-Chlorophenyl)Glycine serves as a key intermediate for several differentiated sectors of fine and specialty chemicals. Our consistent in-house synthesis and strict quality protocols ensure suitability across diverse, highly regulated downstream processes. Below, we detail major application channels driving industrial utilization, with domain-specific compliance, process, and product insights.

1. Pharmaceutical Intermediates for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

This compound functions as a critical chiral building block in the synthesis of advanced NSAID molecules, particularly derivatives of fenamic acid series. Leading pharmaceutical manufacturers employ it in the formation of enantiomerically pure intermediates, enhancing target selectivity during final API development. Integration starts during early-stage chemical synthesis where stereochemistry control impacts subsequent pharmacological activity. Compliance and formulation demand full traceability and impurity management from our production batch to the finished product line, with formulation teams adjusting concentration based on downstream pharmacokinetics and scalability.

Industry compliance standards

• ICH Q7 GMP for Active Pharmaceutical Ingredients
• European Pharmacopoeia (Ph. Eur.) monographs for related APIs
• 21 CFR Part 211 US FDA regulations
• Chinese Pharmacopoeia (ChP) GB standards for APIs and key intermediates

Typical usage ratio

• 15-30% of total synthetic mass in initial condensation reaction, adjusted according to target yield and chiral purity control requirements in API manufacture

Downstream process integration

• Chiral amide or ester formation under anhydrous conditions
• Stirred reactor introduction at precise temperature and pH ranges between 45–80°C
• Monitored by chiral HPLC during reaction and post-processing to ensure enantiomeric excess
• Debottlenecking integration points mainly in early-stage synthesis prior to key cyclization and aromatization processes

Final product types

• Enantiomer-selective NSAID drug substances (e.g., mefenamic acid derivatives)
• High-purity pharmaceutical intermediates for contract manufacturing
• Finished generic and branded NSAID tablets and injectables

2. Agrochemical Synthesis for Aryl Glycine-based Herbicides

The molecule enters agrochemical production chains as a core chiral input for selective herbicide actives containing aryl glycine motifs. Its stable configuration allows process engineers to achieve high-yield coupling reactions without racemization. Close monitoring during scale-up ensures compliance with international crop protection regulations, as any upstream impurity can carry through to regulated end-use formulations. Downstream partners primarily use it in the amidation or acylation step, adjusting concentration for process economy depending on purity and downstream formulation requirements.

Industry compliance standards

• FAO/WHO Specifications for Plant Protection Products
• REACH (EC No. 1907/2006) registration and documentation requirements
• US EPA 40 CFR Part 158 data requirements for active ingredient synthesis
• ISO 9001:2015 certified process traceability

Typical usage ratio

• 8-20% by molar ratio in main coupling or condensation steps, adjusted based on herbicide target structure and level of process impurity control

Downstream process integration

• Nucleophilic substitution or activation with acid chlorides
• Mixing in sealed jacketed reactors with controlled exothermic profiles
• QC sampling at every major process hold point for residual monomer assessment
• Early-stage intermediate for further functional group elaboration or downstream formulation blending

Final product types

• Selective aryl glycine herbicide technical concentrates
• Granular and liquid herbicide formulations for field application
• Contract-manufactured crop protection active ingredients

3. Chiral Auxiliaries and Ligand Manufacturing for Asymmetric Synthesis

Chemical manufacturers leverage this glycine derivative as a raw input for advanced chiral auxiliaries and ligand synthesis in asymmetric catalysis applications. Researchers and commercial teams alike source high enantiopurity material to facilitate the production of metal-complexed catalysts for enantioselective transformations. Our lot-specific batch testing underpins compliance with identification and purity requirements dictated by catalyst and fine chemical downstream users, where chiral integrity and impurity traceability are paramount for predictable process outcomes.

Industry compliance standards

• ISO 17034 Reference Material Producer certification for chiral purity
• GLP (Good Laboratory Practice) for catalyst and auxiliary testing
• In-house specifications for high-purity ligand precursor materials
• Project-specific standards for research and development scale-up batches

Typical usage ratio

• 5-25% of total catalyst or chiral auxiliary precursor batch, modulated based on end-use enantioselectivity requirements

Downstream process integration

• Ligand complexation with transition metals in dry, inert atmosphere reactors
• Covalent linkage to polymer supports or activated carbon in flow chemistry setups
• Strict batch recording for traceability during catalyst library preparation
• Final chiral auxiliary work-up with minimal solvent to avoid racemization

Final product types

• Chiral phosphine or amine ligand compounds
• Enantiopure catalyst libraries for pharmaceutical synthesis
• Specialty chiral auxiliaries for fine chemical custom reactions

4. Specialty Intermediate for Synthesis of Imaging Agents and Fine Chemical Probes

Research-driven chemical producers utilize this molecule to synthesize high-value imaging precursors and molecular probes, especially for rare isotope-labeled glycine derivatives deployed in analytical and diagnostic sectors. Such processes demand rigorous documentation of isotopic labeling integrity and control of organic impurities. Our controlled synthetic route ensures minimal by-products and supports downstream radiochemical conjugation or fluorescent tagging, with traceability documentation critical for analytical reliability and regulatory dossiers.

Industry compliance standards

• USP guidelines for radiopharmaceutical intermediates and precursors
• ISO 13485 for medical device component manufacturing
• OECD Good Manufacturing Practice (GMP) for diagnostic reagent production
• Local nuclear regulatory frameworks for isotope handling

Typical usage ratio

• 5-12% by molar content in isotope labeling reactions, modulated to match the detection sensitivity and purity required for the specific imaging agent

Downstream process integration

• Primary substrate in nucleophilic substitution for radiolabeling under controlled temperature and shielding
• Feeds into late-stage tagging or conjugation within GMP-certified cleanrooms
• QC and analytical verification via LC-MS and NMR at pre- and post-synthesis stages
• Release under batch-specific documentation for traceable end-use in clinical or research imaging

Final product types

• Radiolabeled glycine analogues for PET and SPECT imaging
• Fluorescent or chromophore-linked chemical probes for life sciences research
• Precursor substances for labeled amino acid tracer kits